Pfizer and Novo Nordisk in Bidding War for Metsera Amid GLP-1 Drug Race

Bidding War for Metsera

• ⚔️ An old-fashioned bidding war is underway between Novo Nordisk and Pfizer for control of Metsera.
• 💡 Pfizer initially had a deal to acquire Metsera to bolster its presence in the GLP-1 arena, where it has struggled against incumbents.

Novo Nordisk's Strategic Offer

• 💰 Novo Nordisk entered the fray with a unique offer: paying Metsera shareholders a large immediate amount upon signing, with the actual acquisition occurring later after antitrust approval.
• ⚖️ Pfizer objected to this structure and filed a lawsuit, with a hearing for a temporary restraining order scheduled.

Escalating Bids and CVRs

• 📈 Pfizer responded by raising its bid to $60 per share plus a $10 contingent value right (CVR) for future drug milestones.
• 🚀 Novo Nordisk countered with a total value of $86.20, comprising $62.20 paid immediately as a dividend and a $24 CVR, which has been deemed superior.
• ⏳ Pfizer is now on the clock to respond to Novo Nordisk's superior offer.

Strategic Importance of GLP-1 Drugs

• 🎯 The intense bidding highlights the product portfolio's value at Metsera and the overall importance of the GLP-1 drug class.
• 🥇 The value in this drug class has largely been captured by leaders like Novo Nordisk and Eli Lilly.

Pfizer's Stance on Novo's Bid

• 🗣️ Pfizer CEO Albert Bourla called Novo Nordisk's offer "illusory", arguing it violates antitrust law and has a high risk of never being consummated.
• 🧐 Bourla suggested that even if Novo's bid is blocked, Metsera could later sell itself to Pfizer.